secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001370053-24-000053
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio Q3 net loss $1.14/shr; cash $458M; Phase 2b data catalysts ahead
---------------------------------------------------------------------------

- Net loss $32.9M ($1.14/shr) vs $37.3M ($1.41/shr) year-ago; nine-month loss $4.46/shr.
- Collaboration revenue $30M in Q3 vs $3.3M year-ago due to Jemperli milestone and royalties.
- Cash and investments $458M; reaffirms cash runway through year-end 2026.
- Top-line Phase 2b data for ANB032 in atopic dermatitis expected December 2024.
- Top-line Phase 2b data for rosnilimab in RA expected February 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005324000053/0001370053-24-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005324000053/anab-20241105.htm
  HTML page:      https://secwatch.observer/filing/0001370053-24-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer